Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States

References

• Ommen SR, Mital S, Burke MA, et al. AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159–e240.
   PubMed Web of Science ®Google Scholar
• Elliott PM, Anastasakis A, Borger MA, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society Of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–2779.
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Society of Thoracic Surgeons, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124(24):2761–2796.
   PubMed Web of Science ®Google Scholar
• Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106–1118.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 1995;92(4):785–789.
   PubMed Web of Science ®Google Scholar
• Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–1254.
   PubMed Web of Science ®Google Scholar
• Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170(11):741–748.
   PubMed Web of Science ®Google Scholar
• Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655–668.
   PubMed Web of Science ®Google Scholar
• Ho CY, For the SHaRe Investigators, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138(14):1387–1398.
   PubMed Web of Science ®Google Scholar
• Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769.
   PubMed Web of Science ®Google Scholar
• Adhikari AS, Trivedi DV, Sarkar SS, et al. β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity. Nat Commun. 2019;10(1):2685.
   PubMed Web of Science ®Google Scholar
• Cytokinetics. REDWOOD-HCM: randomized evaluation of dosing with CK-3773274 in obstructive outflow disease in HCM (REDWOOD-HCM) [updated 2021 May 7; cited 2021 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04219826.
   Google Scholar
• Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10293):2467–2475.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Harikrishnan P, Andries G, et al. TCT-831 differences in Short-Term outcomes and cost between alcohol septal ablation and septal myectomy for hypertrophic cardiomyopathy in the United States. J Am Coll Cardiol. 2018;72(13):B331.
   Web of Science ®Google Scholar
• Gul MH, Htun ZM, Aung TK, et al. Abstract 18228: Placement of implantable cardioverter defibrillator in hypertrophic obstructive cardiomyopathy with paroxysmal ventricular tachycardia and their outcomes. Circulation. 2017;136(Suppl_1):A18228.
   Google Scholar
• Jan AS, Rehman S, Rungatscher A, et al. Hypertrophic obstructive cardiomyopathy and the cost of treatment. EJCM. 2016;4(2):27–32.
   Google Scholar
• IBM Watson Health. IBM MarketScan research databases for health services researchers [updated 2019; cited 2021 Jun 1]. Available from: https://www.ibm.com/downloads/cas/6KNYVVQ2.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Hubbard AE, Ahern J, Fleischer NL, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010;21(4):467–474.
   PubMed Web of Science ®Google Scholar
• Tripathi B, Khan S, Arora S, et al. Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization. J Arrhythmia. 2019;35(4):612–625.
   PubMed Web of Science ®Google Scholar
• Urbich M, Globe G, Pantiri K, et al. A. A systematic review of medical costs associated with heart failure in the USA (2014–2020). Pharmacoeconomics. 2020;38(11):1219–1236.
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313–320.
   PubMed Web of Science ®Google Scholar
• Kempf J, Buysman E, Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. Am Health Drug Benefits. 2011;4(6):353–361.
   PubMedGoogle Scholar